TALESSA L POWELL
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- GREENFIELD, IN
- NPI
- 1629162987
- Received
- $37,171 in 73 records, 2019 to 2025 ($2,801 general, $34,369 research)
- As principal investigator
- $1,443,152 of research payments to others in 548 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 3 | $93 |
| 2024 | General payment | 5 | $88 |
| 2024 | Research payment | 1 | $30,748 |
| 2023 | General payment | 9 | $170 |
| 2023 | Research payment | 2 | $1,510 |
| 2022 | General payment | 1 | $16 |
| 2022 | Research payment | 7 | $1,862 |
| 2021 | General payment | 1 | $123 |
| 2021 | Research payment | 1 | $248 |
| 2020 | General payment | 2 | $58 |
| 2019 | General payment | 41 | $2,251 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 5 | $32,804 | 2021–2024 |
| Novo Nordisk AS | 10 | $3,348 | 2019–2022 |
| GlaxoSmithKline, LLC. | 10 | $176 | 2023–2025 |
| Lilly USA, LLC | 10 | $142 | 2019 |
| Novo Nordisk Inc | 10 | $131 | 2019–2025 |
| Biohaven Pharmaceuticals, Inc. | 1 | $123 | 2021 |
| Janssen Pharmaceuticals, Inc | 2 | $83 | 2019–2020 |
| Exact Sciences Corporation | 4 | $75 | 2023–2025 |
| AstraZeneca Pharmaceuticals LP | 5 | $62 | 2019–2020 |
| E.R. Squibb & Sons, L.L.C. | 4 | $48 | 2019 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $46 | 2019 |
| PFIZER INC. | 3 | $43 | 2019–2023 |
| SANOFI-AVENTIS U.S. LLC | 2 | $22 | 2019 |
| Novartis Pharmaceuticals Corporation | 1 | $17 | 2019 |
| Abbott Laboratories | 1 | $16 | 2019 |
| Amarin Pharma, Inc. | 1 | $13 | 2019 |
| Amgen Inc. | 1 | $12 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 11 | $34,369 |
| Food and Beverage | 58 | $1,583 |
| Travel and Lodging | 3 | $1,209 |
| Education | 1 | $8 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-11-19 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-05-07 | Novo Nordisk Inc | $65 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-03-25 | Exact Sciences Corporation | $14 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2025 | |
| 2024-09-24 | Eli Lilly and Company | $30,748 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 | |
| 2024-09-05 | Exact Sciences Corporation | $21 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2024 | |
| 2024-08-22 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2024 | |
| 2024-06-19 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | AREXVY Drug, RESPIRATORY | 2024 | |
| 2024-04-23 | Exact Sciences Corporation | $19 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2024 | |
| 2024-01-08 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2024 | |
| 2023-11-08 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-10-26 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2023 | |
| 2023-09-07 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-07-27 | Exact Sciences Corporation | $20 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2023 | |
| 2023-07-25 | GlaxoSmithKline, LLC. | $22 | Food and Beverage | In-kind items and services | AREXVY Drug, RESPIRATORY | 2023 | |
| 2023-06-16 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-25 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | AREXVY Drug, RESPIRATORY | 2023 | |
| 2023-04-28 | Eli Lilly and Company | $995 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-04-27 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-01-25 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2023 | |
| 2023-01-22 | Eli Lilly and Company | $515 | Research payment | In-kind items and services | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: | 2023 | |
| 2022-05-13 | Novo Nordisk AS | $125 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-05-12 | Novo Nordisk AS | $291 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-05-11 | Novo Nordisk AS | $592 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-05-11 | Novo Nordisk AS | $314 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-05-11 | Novo Nordisk AS | $149 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-05-11 | Novo Nordisk AS | $92 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-05-10 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2022 | |
| 2022-04-29 | Eli Lilly and Company | $298 | Research payment | In-kind items and services | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: | 2022 | |
| 2021-09-15 | Biohaven Pharmaceuticals, Inc. | $123 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 | |
| 2021-03-29 | Eli Lilly and Company | $248 | Research payment | In-kind items and services | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: | 2021 | |
| 2020-03-11 | Janssen Pharmaceuticals, Inc | $45 | Food and Beverage | In-kind items and services | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-01-09 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | 2020 | ||
| 2019-12-19 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-12-17 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2019 | |
| 2019-12-11 | AstraZeneca Pharmaceuticals LP | $11 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-12-10 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2019 | |
| 2019-11-12 | E.R. Squibb & Sons, L.L.C. | $10 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2019 | |
| 2019-10-31 | Novo Nordisk Inc | $4 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2019 | |
| 2019-10-17 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-10-16 | Janssen Pharmaceuticals, Inc | $37 | Food and Beverage | In-kind items and services | INVOKANA Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-08-29 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2019 | |
| 2019-08-22 | Amarin Pharma, Inc. | $13 | Food and Beverage | In-kind items and services | Vascepa Drug, Hypertriglyceridemia | 2019 | |
| 2019-08-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-07-31 | Lilly USA, LLC | $0 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2019 | |
| 2019-07-30 | Lilly USA, LLC | $7 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2019 | |
| 2019-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-07-11 | Lilly USA, LLC | $8 | Education | In-kind items and services | 2019 | ||
| 2019-07-09 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2019 | |
| 2019-07-09 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2019 | |
| 2019-06-15 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | FreeStyle Libre Device, Diabetes Care | 2019 | |
| 2019-06-13 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2019 | |
| 2019-05-16 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2019 | |
| 2019-05-09 | SANOFI-AVENTIS U.S. LLC | $11 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Drug, DIABETES | 2019 | |
| 2019-05-02 | Lilly USA, LLC | $8 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2019 | |
| 2019-05-01 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | LYRICA Drug, NEUROSCIENCE;PAIN | 2019 | |
| 2019-04-17 | Lilly USA, LLC | $57 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2019 | |
| 2019-04-17 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2019 | |
| 2019-04-17 | Lilly USA, LLC | $5 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2019 | |
| 2019-04-11 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Xultophy 100/3.6 Drug, Diabetes | 2019 | |
| 2019-04-01 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-03-14 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2019 | |
| 2019-03-14 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2019 | |
| 2019-03-14 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-03-12 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-02-26 | Novo Nordisk AS | $585 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-02-26 | Novo Nordisk AS | $574 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-02-26 | Novo Nordisk AS | $476 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-02-26 | Novo Nordisk AS | $147 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-02-19 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-02-12 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2019 | |
| 2019-01-24 | SANOFI-AVENTIS U.S. LLC | $10 | Food and Beverage | In-kind items and services | TOUJEO Drug, DIABETES | 2019 | |
| 2019-01-17 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-01 | Boehringer Ingelheim International GmbH | American Health Network-Greenfield | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-11-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | American Health Network-Greenfield | $391 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | American Health Network-Greenfield | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | American Health Network-Greenfield | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | American Health Network-Greenfield | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | American Health Network-Greenfield | $86 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | American Health Network-Greenfield | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | American Health Network-Greenfield | $23 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | American Health Network-Greenfield | $24 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-05-27 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $65 | LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH | 2025 |
| 2025-04-21 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $11,070 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-04-21 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $500 | EX9924-4473 | 2025 |
| 2025-03-31 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $5,178 | EX9924-4473 | 2025 |
| 2025-03-10 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $3,900 | LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH | 2025 |
| 2025-02-21 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $2,250 | EX9924-4473 | 2025 |
| 2025-01-31 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $186 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-27 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $1,443 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-01-07 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $113,777 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2024-12-02 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $2,200 | EX9924-4473 | 2024 |
| 2024-12-02 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $15,980 | LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH | 2024 |
| 2024-11-20 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $828 | EX9924-4473 | 2024 |
| 2024-10-28 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $109 | LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH | 2024 |
| 2024-09-20 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $1,485 | EX9924-4473 | 2024 |
| 2024-08-23 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $1,390 | EX9924-4473 | 2024 |
| 2024-07-22 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $500 | EX9924-4473 | 2024 |
| 2024-07-22 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $4,347 | EX9924-4473 | 2024 |
| 2024-06-21 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $430 | EX9924-4473 | 2024 |
| 2024-05-29 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $159 | EX9924-4473 | 2024 |
| 2024-05-29 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $159 | EX9924-4473 | 2024 |
| 2024-05-29 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $1,290 | EX9924-4473 | 2024 |
| 2024-05-29 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $159 | EX9924-4473 | 2024 |
| 2024-04-30 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $1,867 | EX9924-4473 | 2024 |
| 2024-04-03 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2024 |
| 2024-03-27 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $1,290 | EX9924-4473 | 2024 |
| 2024-03-04 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $9,332 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-02-29 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $860 | EX9924-4473 | 2024 |
| 2024-02-06 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $7 | EX9924-4473 | 2024 |
| 2024-02-06 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2024 |
| 2024-02-06 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $75 | EX9924-4473 | 2024 |
| 2024-01-31 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $739 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-25 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $6,420 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 |
| 2024-01-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $430 | EX9924-4473 | 2024 |
| 2024-01-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $25,000 | EX9536-4388 | 2024 |
| 2024-01-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $1,500 | EX9536-4388 | 2024 |
| 2024-01-03 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2024 |
| 2024-01-02 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $298,063 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 |
| 2023-12-18 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $1,794 | EX9924-4473 | 2023 |
| 2023-11-22 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $2,678 | EX9924-4473 | 2023 |
| 2023-10-30 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $58,590 | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH | 2023 |
| 2023-10-20 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $1,662 | EX9924-4473 | 2023 |
| 2023-10-04 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2023 |
| 2023-10-03 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $43,288 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-09-22 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $2,027 | EX9924-4473 | 2023 |
| 2023-09-08 | Eli Lilly and Company | AMERICAN HEALTH NETWORK OF IN LLC | $3,172 | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH | 2023 |
| 2023-08-18 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $765 | EX9924-4473 | 2023 |
| 2023-08-18 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $6,547 | EX9536-4388 | 2023 |
| 2023-08-08 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2023 |
| 2023-08-04 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $3,025 | EX9536-4388 | 2023 |
| 2023-07-21 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2023 |
| 2023-07-05 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2023 |
| 2023-07-02 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2023 |
| 2023-06-23 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $2,162 | EX9924-4473 | 2023 |
| 2023-06-23 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $3,118 | EX9536-4388 | 2023 |
| 2023-05-26 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $9,704 | EX9536-4388 | 2023 |
| 2023-05-26 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $382 | EX9924-4473 | 2023 |
| 2023-05-12 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $20 | EX9536-4388 | 2023 |
| 2023-05-09 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2023 |
| 2023-04-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $50 | EX9924-4473 | 2023 |
| 2023-04-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $1,080 | NN9535-4352 | 2023 |
| 2023-04-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $600 | EX9536-4388 | 2023 |
| 2023-04-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $500 | EX9536-4388 | 2023 |
| 2023-04-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $689 | EX9536-4388 | 2023 |
| 2023-04-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $2,076 | EX9536-4388 | 2023 |
| 2023-04-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $500 | EX9924-4473 | 2023 |
| 2023-04-21 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $100 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $74 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $45 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $39 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $39 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $89 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $81 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $80 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $46 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $27 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-13 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $84 | EX9924-4473 | 2023 |
| 2023-04-05 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $23 | EX9924-4473 | 2023 |
| 2023-03-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $5,848 | EX9536-4388 | 2023 |
| 2023-03-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK OF INDIANA LLC | $2,283 | EX9924-4473 | 2023 |
| 2023-03-24 | Novo Nordisk AS | AMERICAN HEALTH NETWORK | $1,000 | EX9536-4388 | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Greenfield, IN, county Hancock County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Greenfield, IN | County Hancock County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 24,940 | 84,037 | 6,851,073 |
| Population, 2020 census P1 | 23,488 | 79,840 | 6,785,528 |
| Median age B01002 | 38.8 | 40.0 | 38.1 |
| Under 18 B01001 | 20.4% | 23.2% | 23.3% |
| 65 and over B01001 | 19.6% | 17.3% | 16.8% |
| Households B11001 | 10,666 | 33,474 | 2,716,009 |
| Foreign born B05002 | 4.1% | 3.3% | 6.3% |
| Median household income B19013 | $76,127 | $93,186 | $71,957 |
| Median family income B19113 | $94,683 | $115,271 | $90,767 |
| Per capita income B19301 | $40,636 | $47,372 | $38,351 |
| Poverty rate B17001 | 5.3% | 4.7% | 12.3% |
| Unemployment rate B23025 | 3.3% | 2.7% | 4.3% |
| Civilian labor force B23025 | 13,438 | 45,671 | 3,472,016 |
| Mean commute (minutes) B08013 | 25.7 | 27.7 | 24.1 |
| Bachelor's degree or higher B15003 | 26.2% | 34.9% | 29.5% |
| Housing units B25001 | 10,744 | 34,370 | 2,976,568 |
| Owner-occupied B25003 | 64.9% | 79.5% | 70.6% |
| Renters B25003 | 35.1% | 20.5% | 29.4% |
| Median home value B25077 | $216,400 | $274,800 | $218,200 |
| Median gross rent B25064 | $1,177 | $1,203 | $1,062 |
| White, not Hispanic B03002 | 89.6% | 88.1% | 75.4% |
| Black B03002 | 2.1% | 3.5% | 9.1% |
| Hispanic or Latino B03002 | 3.2% | 3.5% | 8.6% |
| Asian B03002 | 1.7% | 1.1% | 2.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greenfield, IN.
Comments